Goldfinch Bio

Goldfinch Bio. It was a biotechnology company focused on discovering and developing precision medicines for patients with kidney disease. Founded in 2016, the company aimed to leverage genetic insights to target specific drivers of renal disorders. Its operations were based in the biotechnology hub of Cambridge, Massachusetts.

Company overview

Goldfinch Bio was established as a private entity with a mission to transform the treatment landscape for serious kidney diseases through a genetics-driven approach. The company's leadership included seasoned executives from the pharmaceutical industry, such as former Genentech executive Abbie Celniker. Its scientific strategy was built on identifying patient subgroups based on molecular pathways, aligning with the broader movement in precision medicine. This approach sought to move beyond traditional, non-specific therapies for conditions like focal segmental glomerulosclerosis.

History and development

The company was launched in 2016 with a substantial $55 million Series A financing round co-led by Third Rock Ventures and GV. This early backing from prominent venture capital firms provided the capital to build its research platform. In 2019, Goldfinch Bio entered into a significant collaboration with Gilead Sciences, which included a $54 million upfront payment and potential milestone payments. However, in 2022, Gilead Sciences terminated this partnership, leading to a strategic review by Goldfinch Bio's board. Subsequently, the company ceased operations and its assets were liquidated.

Therapeutic focus and pipeline

The company's research concentrated on chronic kidney disease and rare genetic renal disorders, with a particular emphasis on diabetic kidney disease and focal segmental glomerulosclerosis. Its lead clinical candidate, GFB-887, was a TRPC5 inhibitor being investigated for patients with proteinuric kidney diseases. The pipeline also included preclinical programs targeting other genetically defined pathways. This work was supported by the company's proprietary Kidney Genome Atlas, a bioinformatics platform designed to match genetic targets with specific patient populations.

Collaborations and partnerships

The most prominent alliance was the multi-year, multi-target collaboration with Gilead Sciences initiated in 2019, which focused on discovering and developing therapies for diabetic kidney disease. Prior to this, Goldfinch Bio had established key research collaborations with academic institutions, including Regenstrief Institute and the University of Michigan. These partnerships were intended to enrich its genetic datasets and validate novel therapeutic targets. The company also worked with various contract research organizations to advance its clinical programs.

Financial and corporate milestones

Initial funding was secured through the 2016 Series A round led by Third Rock Ventures. The 2019 deal with Gilead Sciences represented a major financial and validation milestone, bringing in immediate non-dilutive capital. In 2020, the company presented positive Phase 1 data for GFB-887 at the American Society of Nephrology Kidney Week meeting. Following the termination of the Gilead Sciences partnership in 2022, the company's board explored strategic alternatives, culminating in the dissolution of the firm and the sale of its assets, including its TRPC5 program.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Defunct biotechnology companies